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AP activity in conditioned media was not increased after 
NSAID treatment of 293-EBNA cells whereas it was elevated 
by phorbol ester. Surprisingly, ibuprofen or indomethacin 
treatment of SH-SY5Y and PC12 cells expressing endoge-
nous APP did not cause changes in sAPP or sAPP-  secretion 
or downregulation of cellular APP. These findings were fur-
ther corroborated in primary chicken neuronal cultures. 
 Conclusions: Using various experimental settings, we were 
unable to confirm sAPP or sAPP-  stimulation with the 
NSAIDs ibuprofen and indomethacin in transfected and 
nontransfected cells of neuronal and nonneuronal origin. 
Importantly, these findings seem to rule out chronic sAPP 
stimulation as an alternative mechanism of NSAID action in 
AD.  Copyright © 2008 S. Karger AG, Basel 
 Introduction 
 Numerous epidemiological studies have supported 
the conclusion that chronic intake of nonsteroidal anti-
inflammatory drugs (NSAIDs) is associated with a lower 
risk of Alzheimer’s disease (AD)  [1] . However, the mech-
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 Abstract 
 Background: Epidemiological studies have suggested that 
long-term use of nonsteroidal anti-inflammatory drugs 
(NSAIDs) is associated with a reduced incidence of Alzhei-
mer’s disease (AD). Several mechanisms have been proposed 
to explain these findings including increased shedding of 
the soluble ectodomain of the amyloid precursor protein 
(sAPP), which functions as a neurotrophic and neuroprotec-
tive factor in vitro  and in vivo.  Objective: To clarify whether 
NSAIDs consistently stimulate sAPP secretion.  Methods: 
293-EBNA cells with stable overexpression of an APP-alka-
line phosphatase fusion protein (APP-AP), SH-SY5Y and PC12 
cells or primary telencephalic chicken neurons were treated 
with ibuprofen or indomethacin. APP shedding was then de-
termined by measuring AP activity in conditioned media, 
Western blot analysis with antibodies against total sAPP or 
specific for sAPP-  , or in a pulse-chase paradigm.  Results: 
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anism of action of these drugs remains unclear, and var-
ious activities that are either related to the anti-inflam-
matory properties of these compounds or are supposed 
to directly target amyloid precursor protein (APP) pro-
cessing, amyloid-  42 (A  42) production and A  aggre-
gation could account for the protective effects of NSAIDs 
in AD  [2] .
 Processing of the APP by   - or   -secretase generates 
large soluble amino-terminal ectodomains, sAPP-  and 
sAPP-  , and corresponding membrane-bound C-termi-
nal fragments (APP-CTFs)  [3] . sAPP has been shown to 
function as a paracrine neurotrophic and neuroprotec-
tive factor in vitro  and in vivo. Biological activities of 
sAPP include promotion of neuronal cell survival, neu-
rite outgrowth, synaptogenesis and synaptic plasticity 
 [4] . Activation of various signal transduction pathways 
modulates sAPP release and the largely predominant 
APP cleavage by   -secretase. For example, stimulation of 
muscarinic/metabotropic receptors enhances sAPP-  se-
cretion through a protein kinase C (PKC)-dependent sig-
naling pathway, and activation of PKC with phorbol es-
ters stimulates sAPP-  secretion by itself  [5, 6] .
 The high-affinity targets of NSAIDs, cyclooxygenases 
(COX), are the central enzymes in prostaglandin synthe-
sis and oxidize arachidonic acid from membrane-bound 
phospholipids to prostaglandins  [7] . Inhibition of COX 
by NSAIDs results in an intracellular buildup of arachi-
donic acid  [8] , and arachidonic acid and its metabolites 
can stimulate PKC activity  [9] . It is therefore plausible 
that inhibition of COX by NSAIDs could lead to in-
creased levels of arachidonic acid metabolites, activation 
of PKC, and subsequent stimulation of sAPP-  secretion. 
In this respect, it has been suggested that sustained treat-
ment (20 h) with nanomolar to low micromolar concen-
trations (0.1–10   M ) of the NSAIDs ibuprofen and indo-
methacin can prominently stimulate secretion of sAPP-  
from endogenous APP in permanent neuronal cell lines 
 [10] . This partially concurred with earlier results that in-
domethacin (25–50   M ) stimulated sAPP secretion from 
a human glioblastoma cell line  [11] , and findings that 
short-term treatment (30 min) with indomethacin (10 
  M ) acutely elevated sAPP-  release from neuronal cells 
 [12] . However, several studies with APP-transfected cell 
lines failed to observe modulation of sAPP or sAPP-  re-
lease with ibuprofen or other NSAIDs  [13–15] . Further-
more, increased levels of arachidonic acid resulted in 
stimulation of sAPP release from endogenous APP in 
PC12 cells and human platelets, but concomitant COX 
inhibition with indomethacin did not potentiate, but par-
tially reversed this stimulation  [16, 17] .
 Clarification of the mechanism of action of NSAIDs in 
AD is a high priority, particularly in regard to ongoing 
drug development efforts that aim for pharmacological 
optimization of individual NSAID activities  [2] . Persis-
tent stimulation of the neurotrophic/neuroprotective 
sAPP ectodomain by NSAIDs could provide yet another 
explanation for the protective effects of NSAIDs in AD. 
We therefore attempted to clarify whether NSAIDs are 
capable of modulating APP shedding and sAPP release 
using a variety of methods to accurately quantify sAPP 
levels. Surprisingly, we were unable to confirm sAPP 
stimulation by the widely used NSAIDs ibuprofen and in-
domethacin in permanent cell lines and primary neuro-
nal cultures. Importantly, these findings seem to exclude 
chronic enhancement of APP ectodomain shedding as an 
alternative mechanism of NSAID action in AD.
 Materials and Methods 
 Drugs and Antibodies 
 The NSAIDs ibuprofen and indomethacin were purchased 
from Biomol (Plymouth Meeting, Pa., USA), and phorbol-12-my-
ristate-13-acetate (PMA) was obtained from Axxora (San Diego, 
Calif., USA). All other chemicals were from Sigma-Aldrich (Mu-
nich, Germany) except when otherwise indicated. Monoclonal 
antibodies (MAbs) IG7/5A3 raised against nonoverlapping epi-
topes in the APP ectodomain between amino acid residues 380–
665, and polyclonal antiserum 863 raised against the mid-region 
of APP detect both sAPP-  and sAPP-   [15, 18] . MAb 26D6 
against amino acid residues 1–12 of the A  sequence detects only 
sAPP-   [15] . Polyclonal antibody CT-15 was raised against the C-
terminal 15 amino acid residues of human APP  [15] .
 Cell Lines, Preparation of Telencephalic Chicken Neurons, 
and Drug Treatments 
 Rat pheochromocytoma PC12 cells, SH-SY5Y human neuro-
blastoma cells, and HEK 293-EBNA cells that stably express a fu-
sion protein consisting of secretory alkaline phosphatase (AP) 
and full-length APP  [19] were maintained in DMEM supplement-
ed with 10% fetal bovine serum (FBS), 2 m M  L -glutamine, 2 m M 
sodium pyruvat and 100 U/ml penicillin/streptomycin (Invitro-
gen, Carlsbad, Calif., USA). Fertilized chicken eggs were obtained 
from Charles River Laboratories (Wilmington, Mass., USA). Tel-
encephalic cortices were dissected from 8-day-old chicken em-
bryos, and neurons were prepared and cultured according to pre-
viously described procedures  [20] . Experiments were carried out 
after 5 days of cultivation in neurobasal medium supplemented 
with B27 supplement, 2 m M  L -glutamine and 100 U/ml penicil-
lin/streptomycin (Invitrogen). At least 24 h before drug treat-
ments, permanent cell lines were transferred to serum-reduced 
medium (0.5% FBS). Cells were then treated for 24 h with increas-
ing concentrations of NSAIDs, PMA or DMSO vehicle. Primary 
chicken neurons were treated in an analogous fashion in serum-
free neurobasal medium. All treatments were carried out in du-
plicates.
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 AP Assay 
 AP activity was measured as described  [19] . Conditioned media 
of 293-EBNA cells were treated for 30 min at 65 ° C to heat-inacti-
vate the endogenous AP activity. Subsequently, 20   l of medium 
were mixed with 200   l substrate solution (0.1  M glycine, pH 10.4, 
1 m M Mg 2 Cl, 1 m M ZnCl 2 containing 1 mg/ml 4-nitrophenyl phos-
phate disodium salt hexahydrate), and incubated for 1 h at room 
temperature in the dark. The reaction was stopped by adding 1/5 
volume 3  M NaOH, and absorbance was read at 405 nm.
 Western Blot and Pulse-Chase Analysis of sAPP Secretion and 
Cellular APP Expression after NSAID Treatment 
 For analysis of endogenous sAPP secretion by Western blot-
ting, 400   l of conditioned cell culture media were mixed with
1  ! complete protease inhibitor cocktail (1  ! PI; Roche Diagnos-
tics GmbH, Mannheim, Germany). Subsequently, supernatants 
were concentrated by centrifugal filters (Microcon YM-50, Mil-
lipore, Schwalbach, Germany) and adjusted with NP40 buffer (1% 
NP40, 50 m M Tris, pH 8.0, 150 m M NaCl, 1  ! PI) to a volume of 
50   l. Equal volumes of concentrates were resolved on 4–12% Bis-
Tris gels (Invitrogen), and total sAPP and sAPP-  levels were de-
termined by Western blotting with MAbs IG7/5A3 or 26D6. In the 
experiments with primary chicken neurons, duplicates from each 
drug concentration were pooled prior to Western blot analysis, 
and total sAPP levels were determined with polyclonal antiserum 
863. Chemiluminescence was recorded with an LAS 3000 ECL 
camera system and quantified with the densitometry software 
AIDA (Fuji Photo Film GmbH, Düsseldorf, Germany). For analy-
sis of cellular APP expression, cells were lysed in NP40 buffer, and 
equal protein amounts were separated on 4–12% Bis-Tris gels and 
analyzed by Western blotting with polyclonal antibody CT-15.
 For pulse-chase analysis of total sAPP release and cellular APP 
levels, PC12 cells were pretreated for 24 h with NSAIDs or DMSO 
vehicle in DMEM with 0.5% FBS. Cells were starved for 30 min in 
DMEM without methionine, metabolically labeled for 20 min 
with 350   Ci [ 35 S]-methionine, and then chased for 4 h in cold 
DMEM with 0.5% FBS in the presence of NSAIDs, PMA or DMSO 
vehicle. Chase media were collected and sAPP was immunopre-
cipitated with MAbs IG7/5A3 and anti-mouse IgG-conjugated 
agarose beads (American Qualex, San Clemente, Calif., USA). 
Corresponding cells were lysed in NP40 buffer, and APP was im-
munoprecipitated with polyclonal antibody CT-15 and rec-protein 
A-sepharose 4B (Invitrogen). Immunoprecipitates were resolved 
on 4–12% Bis-Tris gels and analyzed by phosphor imaging.
 Statistical Analysis 
 Dose-response experiments were repeated at least 3 times, and 
results were normalized to DMSO control condition and ana-
lyzed by one-way ANOVA with Dunnett’s post hoc tests and drug 
concentration as categorical variable. Statistics were performed 
using GraphPad Prism software (GraphPad Software, San Diego, 
Calif., USA).
 Results and Discussion 
 In previous studies using APP-transfected CHO cells, 
we demonstrated that the NSAID sulindac sulfide did not 
affect levels of total sAPP, sAPP-  , APP-CTFs or APP 
holoprotein expression by Western blotting  [15] . Similar 
results have been reported with other NSAIDs including 
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 Fig. 1. NSAIDs did not modulate APP ectodomain shedding in an 
sAPP reporter cell line.  293 cells with a stable expression of a fu-
sion protein consisting of AP and APP were treated for 24 h with 
ibuprofen, indomethacin or PMA, and AP activity in conditioned 
media was quantified with a colorimetric assay. Stimulation of the 
  -secretase pathway with PMA induced a 4-fold increase in AP 
activity. In contrast, neither ibuprofen ( a ) nor indomethacin ( b ) 
treatment had any effect on sAPP release and AP activity: n = 4, 
one-way ANOVA,  * p  ! 0.01 Dunnett’s post hoc tests. 
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 Fig. 2. NSAIDs did not stimulate sAPP-  release from endoge-
nous APP in neuronal cell lines. Human SH-SY5Y cells ( a ,  b ) or 
rat PC12 cells ( c ,  d ) were treated for 24 h with ibuprofen or indo-
methacin, and sAPP-  release in conditioned media was detected 
by Western blotting with MAb 26D6 against amino acid residues 
1–12 of the human A  sequence. In corresponding cell lysates, 
APP holoprotein levels were analyzed with antibody CT-15 against 
the C-terminal 15 amino acid residues of human APP. Ibuprofen 
( a ,  c ) and indomethacin ( b ,  d ) treatments exerted no significant 
effects on sAPP-  release or cellular APP expression levels. For 
quantification of sAPP-  levels, results from 3 independent ex-
periments carried out in duplicate were averaged and analyzed by 
one-way ANOVA. Representative Western blotting results for 
sAPP-  and cellular APP are shown below. 
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ibuprofen in APP-transfected HEK 293 and N2a cells  [13, 
14] . To further substantiate these findings, we treated a 
HEK-293-based sAPP reporter cell line with low to high 
concentrations (0.01–250   M ) of the NSAIDs ibuprofen 
and indomethacin. These cells stably express a fusion 
protein consisting of secretory AP and full-length APP, 
and allow precise quantification of APP ectodomain 
shedding by determination of AP activity in conditioned 
media with a simple colorimetric assay  [19] . Neither ibu-
profen ( fig. 1 a) nor indomethacin ( fig. 1 b) displayed any 
stimulating effects on APP ectodomain shedding in this 
assay. As a positive control, cells were treated with the 
phorbol ester PMA, which enhances   -secretase-medi-
ated cleavage of APP  [5, 6] . As previously reported  [19] , 
PMA treatment increased AP activity around 4-fold 
demonstrating that the shedding machinery was not sat-
urated in this culture system ( fig. 1 ).
 Avramovich et al.  [10]  have reported that sustained 
treatment (20 h) of neuronal SH-SY5Y or PC12 cells with 
ibuprofen or indomethacin prominently stimulated gen-
eration of sAPP-  . In this study, a bimodal effect of 
NSAID treatment was observed with a maximal stimula-
tion of sAPP-  levels at low micromolar concentrations 
(0.1–10   M ) and reductions in sAPP-  levels at higher 
concentrations (100   M ). In addition, elevations in sAPP-
  levels after NSAID treatment were accompanied by re-
ductions in levels of cellular APP holoprotein  [10] . These 
experiments differed from our own and other studies in 
three significant ways  [13–15] . First, they were performed 
in neuronal cell lines and it seemed possible that modula-
tion of APP ectodomain shedding occurs only in cells of 
neuronal origin but not in peripheral cell lines. Second, 
whereas we and others used cell lines with ectopic expres-
sion of APP  [13–15] , this study described sAPP-  stimu-
lation from endogenous APP  [10] . This aspect could have 
provided an explanation for the divergent results, for in-
stance if NSAIDs promoted stimulation of the endoge-
nous APP promoter or stabilization of APP protein levels, 
thereby generating more substrate for   -secretase. Third, 
lower NSAID concentrations were explored and found to 
be effective  [10] .
 To exclude that any of these possibilities might have 
prevented us from detecting stimulating effects of 
NSAIDs on APP ectodomain shedding, we attempted to 
reproduce the results by Avramovich et al.  [10] with in-
terchangeable experimental approaches. SH-SY5Y or 
PC12 cells were treated under low-serum conditions with 
0.1–100   M of ibuprofen or indomethacin, and sAPP-  
and total sAPP levels in conditioned media were quanti-
fied by Western blotting. Detection of sAPP-  with MAb 
26D6 did not reveal modulatory effects of ibuprofen or 
indomethacin in SH-SY5Y ( fig. 2 a, b) or PC12 cells 
( fig. 2 c, d) over the entire concentration range. Similar 
negative results were obtained when total sAPP levels in 
PC12 cells were detected with MAbs IG7/5A3 directed 
against N-terminal epitopes in the APP ectodomain (data 
not shown). We also analyzed corresponding cell lysates 
with polyclonal antibody CT-15 against the C-terminus 
of APP. No changes in steady-state levels of APP were ob-
served after NSAID treatment ( fig. 2 ).
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 Fig. 3. Pulse-chase analysis of sAPP release after NSAID treat-
ment in PC12 cells. PC12 cells were pretreated for 24 h with the 
indicated concentrations of NSAIDs, labeled with [ 35 S]-methio-
nine, and chased for 4 h with cold medium in the presence of 
NSAIDs or PMA. sAPP was immunoprecipitated from condi-
tioned media with MAbs IG7/5A3 against the APP ectodomain, 
and APP holoprotein levels were analyzed in corresponding cell 
lysates with antibody CT-15 against the C-terminus of APP. As 
expected, PMA treatment increased sAPP levels and decreased 
mature APP holoprotein ( a ). However, ibuprofen ( a ) or indometh-
acin ( b ) treatments did not stimulate sAPP generation or lower 
APP holoprotein levels. 
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 Fig. 4. sAPP release after NSAID treatment in primary neuronal 
cultures. Primary telencephalic chicken neurons were treated af-
ter 5 days in culture for 24 h with ibuprofen or indomethacin. 
sAPP-  and total sAPP levels were analyzed in conditioned media 
with the sAPP-  -specific MAb 26D6 or the polyclonal antiserum 
863 raised against the mid-region of APP. APP holoprotein levels 
in corresponding cell lysates were detected with antibody CT-15 
against the C-terminus of APP. In accordance with the results in 
permanent cell lines, neither ibuprofen ( a ) nor indomethacin ( b ) 
treatment resulted in significant changes in sAPP-  , total sAPP 
or cellular APP levels. For quantification of sAPP-  and total 
sAPP levels, results from 3 independent experiments were aver-
aged and analyzed by one-way ANOVA. Representative Western 
blotting results for sAPP-  , total sAPP and cellular APP are 
shown below. 
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 To further confirm these results, total sAPP levels af-
ter NSAID treatment were examined in a pulse-chase 
paradigm. PC12 cells were pretreated for 24 h with the 
indicated concentrations of ibuprofen and indomethacin, 
labeled for 20 min with [ 35 S]-methionine containing me-
dium, and subsequently chased for 4 h with cold medium 
in the presence of NSAIDs or PMA. sAPP was immuno-
precipitated from conditioned media with MAbs IG7/
5A3, and APP holoprotein levels were analyzed in corre-
sponding cell lysates with antibody CT-15. As expected, 
PMA treatment increased sAPP levels and decreased ma-
ture cell-associated APP holoprotein ( fig. 3 a). However, 
ibuprofen ( fig. 3 a) or indomethacin ( fig. 3 b) treatment 
failed to stimulate sAPP generation or lower cellular APP 
holoprotein.
 Finally, we intended to corroborate our findings in a 
primary neuronal culture system. For these experiments, 
primary telencephalic chicken neuronal cultures were 
chosen because of the identity between the chicken A  
sequence and the human sequence  [20] . For that reason, 
detection of endogenous sAPP-  species in chicken neu-
rons is feasible with available human-specific A  anti-
bodies. Neurons were treated after 5 days in culture with 
0.1–250   M of ibuprofen or indomethacin, and condi-
tioned media and corresponding cell lysates were ana-
lyzed by Western blotting as described above. In agree-
ment with our results in permanent cell lines, neither ibu-
profen ( fig. 4 a) nor indomethacin ( fig. 4 b) treatment 
resulted in significant changes in sAPP-  , total sAPP, or 
cellular APP levels.
 In summary, we have been unable to confirm modula-
tion of APP ectodomain shedding with the NSAIDs ibu-
profen and indomethacin. The underlying reasons for the 
obvious inconsistencies between our results and previous 
studies remain unclear  [10, 11] , but we consider it unlike-
ly that minor experimental differences between studies 
could explain the divergent outcomes. Ibuprofen and in-
domethacin belong to the most frequently prescribed 
NSAIDs. Accordingly, these drugs should have made a 
substantial contribution to the reported inverse correla-
tion between NSAID use and AD risk as revealed in many 
epidemiological studies. For example in the Rotterdam 
Study, a prospective study of almost 7,000 subjects, which 
described an 80% risk reduction for AD associated with 
NSAID use, ibuprofen and indomethacin accounted for 
about 26% of all NSAID prescriptions  [21] . Furthermore, 
in clinical trials, indomethacin was the only NSAID re-
ported to provide slowing of symptom progression in AD 
patients  [22] . Consequently, we believe that our compre-
hensive studies in APP-transfected and nontransfected 
cell culture systems of neuronal and nonneuronal origin 
provide compelling evidence that chronic stimulation of 
sAPP release is not a relevant activity of these compounds 
and not an alternative mechanism of action of NSAID in 
AD.
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